Fixed-dose combination bictegravir–emtricitabine–tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): a phase 2b, open-label, randomised non-comparative trial
Year: 2025
Type: article
Study design: Clinical Trial
Source: The Lancet HIV
Authors: Anushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, Roeland E Wasmann, Gillian Dorse, Rubeshan Perumal, Mahomed-Yunus S Moosa, Emmanuella C Osuala, Resha Boodhram, Benjamin Chimukangara, Lubbe Wiesner, Dennis Israelski, Paolo Denti, James F Rooney, Kelly E Dooley, Anushka Naidoo, Kelly E. Dooley, Kogieleum Naidoo, Gillian Dorse, Rubeshan Perumal, Resha Boodhram, Busisiwe Ntsalaze, Samiksha Byroo, Ellisha Francis, Anokhee Leela, Rosemary Gray, Bhavna Maharaj, Nompumelelo Zungu, Phindile Msomi, Claudia Shozi, Radhamoney Narasimmulu, Nokuzola Cwazibe, Rajesperi Venter, Saras Pather, Nokwanda Depargo, Silindile Tenza, Patience Mbatha, Marothi P. Letsoalo, Mxolisi Mahlangu, Natasha Samsunder, Zanele Mchunu, Avanthi Moodley-Reddy, Lungile Maphumulo, Adejumoke Abiose, Emmanuella C. Osuala
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Dolutegravir for the treatment of HIV in patients with Tuberculosis in KwaZulu-Natal South Africa, Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa, G2860292804, Mentoring Investigators in HIV and Tuberculosis Therapeutics Research
OpenAlex ID: W4417076775